Does bivalirudin improve rates of ischemia and bleeding in patients with moderate- or high-risk acute coronary syndromes undergoing invasive treatment compared to heparin?
In patients with moderate- or high-risk acute coronary syndromes undergoing invasive management, bivalirudin alone provides similar ischemic protection with significantly less bleeding compared to heparin.
In patients with moderate- or high-risk acute coronary syndromes who were undergoing invasive treatment with glycoprotein IIb/IIIa inhibitors, bivalirudin was associated with rates of ischemia and bleeding that were similar to those with heparin. Bivalirudin alone was associated with similar rates of ischemia and significantly lower rates of bleeding. (ClinicalTrials.gov number, NCT00093158 ClinicalTrials.gov.).
Stone et al. (Wed,) studied this question.